BEVERLY HILLS, Calif.- GT Biopharma, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE™ for cancer and infectious diseases, today announced the addition of a new clinical trial site for its ongoing...
Latest News
BEVERLY HILLS, Calif. – GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial...
BEVERLY HILLS, Calif. – GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform, announced today additional interim results from its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of...
BEVERLY HILLS, Calif. – GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce updated interim Phase I/II clinical trial results for the Company’s lead therapeutic candidate, GTB-3550, being...
– GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors – Compared to monomeric IL-15, GTB-5550 shows CD16-dependent metabolic activation of NK cells BEVERLY HILLS, Calif., – GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the...
TEMPE, Ariz. — GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced that the first patients have been enrolled in the Beginning Radiation Immediately with GammaTile® at Glioblastoma Excision versus Standard of Care (BRIDGES) U.S. clinical trial for newly diagnosed glioblastoma (GBM)....
Gwangju, South Korea – Metabolic dysfunction-associated steatotic liver disease (MASLD) is a burgeoning global health concern, posing a significant threat to public health and escalating the burden on healthcare resources. Characterized by the accumulation of fat in the liver, MASLD increases the risk of progressing to more severe conditions such...
BARCELONA, Spain — Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01 following authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS). The study will evaluate GYA01, a first-in-class CAR-T cell therapy targeting...
TAMPA, Fla. — Multiple myeloma remains challenging to treat. New therapeutic advances have improved outcomes, but selecting the right treatment for a patient can be complex because the disease can vary drastically from person to person. In a new article published in the Journal of Clinical Oncology, Moffitt Cancer Center...
TAMPA, Fla. — Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Roughly 90% of men with advanced prostate cancer will develop...